US Patent Issued to Amgen on Feb. 10 for "Use of GDF15 for treating cardiometabolic syndrome and other conditions" (California Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,427, issued on Feb. 10, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Use of GDF15 for treating cardiometabolic syndrome and other conditions" was invented by Murielle Marie V. Ellison (Thousand Oaks, Calif.), Clarence H. Hale (Camarillo, Calif.), Xin Luo (San Francisco) and Marina Stolina (Beverly Hills, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides a method of treating cardiometabolic syndrome (CMS) with a GDF15 molecule. Also provided herein is a method of treating a cardiac or heart condition. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc reg...